Quantcast

Latest MedImmune Stories

2011-08-11 07:00:00

BEIJING, Aug. 11, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it has obtained the GMP certificate for its seasonal flu vaccine and hepatitis A vaccine from the Mexican regulatory authority, the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) of Mexico Ministry of Health. Sinovac is the first Chinese vaccine manufacturer to be granted GMP certificate by COFEPRIS. The GMP...

2011-08-04 06:48:00

CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate selected by AstraZeneca from its collaborative research program with Palatin Technologies. Obesity is a global problem, with the World Health...

2011-08-04 03:00:00

DALLAS, August 4, 2011 /PRNewswire/ -- ReportsnReports announces it will carry reports on Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market in its store A.Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics [http://www.reportsnreports.com/reports/117995-needle-free-drug-delivery-the-market-for-alternatives-to-needle-.html ] The coming decade will see drug delivery...

2011-07-26 20:50:25

Follow-up dose recommended to defend children against pandemic virus outbreak Researchers from Australia determined that pediatric liver transplant patients who received a single-dose of the H1N1 vaccine were not adequately protected against the virus compared to healthy children. This study appearing in the August issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases, found that a second vaccination was needed to elicit an effective immune...

2011-07-18 11:00:00

GAITHERSBURG, Md., July 18, 2011 /PRNewswire/ -- MedImmune announced today that it has begun shipping FluMist® (Influenza Vaccine Live, Intranasal) to influenza vaccine distributors who service health care providers throughout the United States. MedImmune expects to provide approximately 15 -16 million doses of its trivalent (three-strain) nasal spray flu vaccine for the 2011-2012 influenza season through a variety of private health care practices, public health...

2011-07-18 05:00:00

GAITHERSBURG, Md., July 18, 2011 /PRNewswire/ -- MedImmune has received confirmation from the U.S. Food & Drug Administration (FDA) that the Agency has filed the Company's supplemental Biologics License Application (sBLA) for a quadrivalent (four-strain) version of FluMist® (Influenza Vaccine Live, Intranasal). The company submitted the sBLA early in the second quarter of this year. Currently licensed seasonal influenza vaccines are trivalent, containing three strains...

2011-07-15 07:20:16

(Ivanhoe Newswire)--Swine flu may be able to be detected through a simple breath test. Researchers have been investigating an easy and non-invasive breath test that measures biomolecules that accumulate in response to the strain caused by H1N1 flu virus. This test could mean a future without vaccination shortages. Those diagnosed with swine flu typically have a fever or high temperature and may also experience aching muscles, sore throat, or a dry cough. The symptoms are very similar to types...

2011-06-30 06:00:00

- Phase II part B confirms results obtained in Phase II part A - - Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - QUEBEC CITY, June 30, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with...

2011-06-23 00:00:00

BANGALORE, India, June 23, 2011 /PRNewswire/ -- Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and AstraZeneca, today announced another successful delivery of an early stage milestone in the Pain therapeutic area. The collaboration, initiated two years ago in the Neuroscience therapeutic area, has now expanded to Cardiovascular and Metabolic diseases and focuses on the delivery of a steady stream of preclinical outcomes to AstraZeneca,...

2011-06-16 02:26:00

NESS ZIONA, Israel, June 16, 2011 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) [http://www.biondvax.com ] today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine. The vaccine was found to be safe and well tolerated, and induced robust immune responses, successfully meeting both the primary safety and immunogenicity endpoints, as well as additional secondary immunogenicity endpoints. It was also...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related